The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.

[1]  James Murray.  Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma , 2013, Thorax.

[2]  Keitaro Matsuo,et al.  DNA Methylation in Peripheral Blood: A Potential Biomarker for Cancer Molecular Epidemiology , 2012, Journal of epidemiology.

[3]  K. Nackaerts,et al.  Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. la Vecchia,et al.  Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[5]  J. Soh,et al.  Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. , 2012, Lung cancer.

[6]  J. Soh,et al.  Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma , 2011, Clinical Cancer Research.

[7]  K. Moons,et al.  Markers for the non-invasive diagnosis of mesothelioma: a systematic review , 2011, British Journal of Cancer.

[8]  Zhaoli Chen,et al.  DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer , 2011, Cancer biology & therapy.

[9]  A. Weber,et al.  Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos , 2011, Archives of Toxicology.

[10]  R. Rosell,et al.  Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  M. Toyota,et al.  Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. , 2010, Carcinogenesis.

[12]  Feng Jiang,et al.  Plasma microRNAs as potential biomarkers for non-small-cell lung cancer , 2010, Laboratory Investigation.

[13]  R. Davies,et al.  Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  N. Maskell,et al.  Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[15]  S. Skates,et al.  Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[16]  Martin Horlitz,et al.  Optimized Quantification of Fragmented, Free Circulating DNA in Human Blood Plasma Using a Calibrated Duplex Real-Time PCR , 2009, PloS one.

[17]  H. Kindler,et al.  Malignant pleural mesothelioma: an update on biomarkers and treatment. , 2009, Chest.

[18]  H. Dienemann,et al.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.

[19]  M. Paci,et al.  Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. , 2009, Lung cancer.

[20]  T. Mok,et al.  Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients , 2009, Clinical Cancer Research.

[21]  Peter A. Jones,et al.  DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight , 2008, Nucleic acids research.

[22]  M. Toyota,et al.  Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. , 2008, Cancer research.

[23]  K. O'Byrne,et al.  Advances in the systemic therapy of malignant pleural mesothelioma , 2008, Nature Clinical Practice Oncology.

[24]  Maurice B Loughrey,et al.  BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype , 2008, Breast Cancer Research.

[25]  M. Copin,et al.  Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment , 2007, Clinical Cancer Research.

[26]  P. Vineis,et al.  Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. , 2007, Mutation research.

[27]  S. Toyooka,et al.  Aberrant promoter methylation of insulin‐like growth factor binding protein‐3 gene in human cancers , 2007, International journal of cancer.

[28]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[29]  Ie-Ming Shih,et al.  Principle and applications of digital PCR , 2004, Expert review of molecular diagnostics.

[30]  V. Ambros.  MicroRNA Pathways in Flies and Worms Growth, Death, Fat, Stress, and Timing , 2003, Cell.

[31]  R. Jaeschke,et al.  A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis , 2003, Intensive Care Medicine.

[32]  J. Minna,et al.  Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells , 2002, Oncogene.

[33]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[34]  K. Kinzler,et al.  Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[36]  Ramon Silva Martins,et al.  Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[37]  Hiromasa Yamamoto,et al.  The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. , 2008, Oncology reports.